These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 140642)
41. Sodium valproate in Sydenham's chorea. Dhanaraj M; Radhakrishnan AR; Srinivas K; Sayeed ZA Neurology; 1985 Jan; 35(1):114-5. PubMed ID: 3917559 [TBL] [Abstract][Full Text] [Related]
42. Isoniazid and Huntington's chorea. Perry TL N Engl J Med; 1978 May; 298(19):1092-3. PubMed ID: 148007 [No Abstract] [Full Text] [Related]
43. Huntington's disease and HDACi: would sulpiride and valproate be of therapeutic value? Tremolizzo L; Rodriguez-Menendez V; DiFrancesco JC; Sala G; Galbussera A; Appollonio I; Ferrarese C Med Hypotheses; 2007; 69(4):964-5. PubMed ID: 17428619 [No Abstract] [Full Text] [Related]
44. [Study of the therapeutic action and side-effects of a new preparation of dipropylacetic acid]. Gallassi R Clin Ter; 1977 Nov; 83(3):313-7. PubMed ID: 342177 [No Abstract] [Full Text] [Related]
45. Sodium valproate in Sydenham's chorea. Kulkarni ML Indian Pediatr; 1992 Mar; 29(3):385-6. PubMed ID: 1612693 [No Abstract] [Full Text] [Related]
46. [Sodium dipropyl acetate in the prevention of febrile convulsions in children]. Galli V; Gatti G; Massolo F; Nalin A; Rozzi N; Tamborino G Acta Neurol (Napoli); 1977; 32(6):884-91. PubMed ID: 343515 [No Abstract] [Full Text] [Related]
47. Sodium valproate in the treatment of intractable seizure disorders: a clinical and electroencephalographic study. Adams DJ; Luders H; Pippenger C Neurology; 1978 Feb; 28(2):152-7. PubMed ID: 414151 [TBL] [Abstract][Full Text] [Related]
48. [Modification of personality changes in epileptics using dipropylacetate (Convulex). Preliminary communication]. Deisenhammer E Wien Med Wochenschr; 1977 Jun; 127(12):370-3. PubMed ID: 333779 [No Abstract] [Full Text] [Related]
49. Current concepts in drug therapy. Ceylon Med J; 1976 Sep; 21(3):208-9. PubMed ID: 800352 [No Abstract] [Full Text] [Related]
50. Progressive myoclonic epilepsy. The response to sodium di -- n -- propylacetate. Tomlinson EB Proc Aust Assoc Neurol; 1974; 11():203-8. PubMed ID: 4620029 [No Abstract] [Full Text] [Related]
51. [Use of sodium dipropylacetate in the prevention of recurrences of febrile convulsions]. Cavazzuti GB Riv Neurol; 1977; 47(2):156-8. PubMed ID: 325627 [No Abstract] [Full Text] [Related]
52. [Clinical--pharmacological aspects of treatment with sodium di-n-propylacetate]. Wulff K; Flachs H; Würtz-Jørgensen A; Gram L Ugeskr Laeger; 1977 May; 139(18):1059-64. PubMed ID: 324057 [No Abstract] [Full Text] [Related]
53. [Treatment of pyknoleptic petit mal epilepsy and juvenile myoclonic epilepsy with dipropyl acetate (Deprakine). A pilot study of therapy-resistant patients during control of plasma concentration]. Schroll M; Naestoft J; Lund M Ugeskr Laeger; 1977 May; 139(18):1073-7. PubMed ID: 404744 [No Abstract] [Full Text] [Related]
54. Influence of a GABA transaminase inhibitor on central nervous system oxygen toxicity. Harel D; Raday-Bitterman N; Kerem D Aviat Space Environ Med; 1978 Jul; 49(7):877-9. PubMed ID: 352331 [TBL] [Abstract][Full Text] [Related]